InflaRx (NASDAQ:IFRX) Announces Quarterly Earnings Results

InflaRx (NASDAQ:IFRX) announced its quarterly earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08, FiscalAI reports.

InflaRx Price Performance

Shares of InflaRx stock traded up $0.15 during trading hours on Thursday, reaching $2.65. The company’s stock had a trading volume of 8,821,881 shares, compared to its average volume of 996,927. The firm has a 50 day moving average price of $1.16 and a 200-day moving average price of $1.12. InflaRx has a one year low of $0.71 and a one year high of $2.95. The stock has a market cap of $191.57 million, a P/E ratio of -3.49 and a beta of 2.42.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Oppenheimer assumed coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 price target on the stock. Guggenheim restated a “buy” rating and issued a $14.00 target price on shares of InflaRx in a report on Tuesday, April 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a report on Friday, March 27th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.80.

Institutional Trading of InflaRx

A number of large investors have recently made changes to their positions in the business. Cubist Systematic Strategies LLC increased its holdings in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock worth $31,000 after buying an additional 7,616 shares during the last quarter. Boothbay Fund Management LLC grew its holdings in InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock valued at $235,000 after purchasing an additional 17,056 shares during the last quarter. Squarepoint Ops LLC grew its holdings in InflaRx by 29.1% during the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after purchasing an additional 42,489 shares during the last quarter. HRT Financial LP bought a new position in InflaRx during the 4th quarter valued at about $47,000. Finally, Insigneo Advisory Services LLC bought a new position in InflaRx during the 4th quarter valued at about $61,000. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.